The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

AstraZeneca and Daiichi Sankyo ’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

Lyndra Therapeutics has announced the immediate appointment of Adam Sayer as its new president and CEO, succeeding Jessica ...

The potential secretary for Health and Human Services has been forced to defend his previous anti-vaccine stances at his ...

A proposed ban on PFAS chemicals is being challenged over concerns about potential supply chain disruption in the ...

The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis pigmentosa (XLRP).

Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) technology.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

This study reinforces the significance of intensive glycaemic control and is a paradigm shift in managing the disease and its ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.